 |
Rh o (D) Immune Globulin (Human) -- Hyper RHO ™ S/D Mini-Dose treated with solvent/detergent is a sterile solution of immune globulin containing antibodies to Rh o (D) for intramuscular administration; it contains no preservative. HyperRHO S/D Mini-Dose is prepared by cold ethanol fractionation from human plasma. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solution is adjusted to a final concentration of 0.3% tri-n-butyl phosphate (TNBP) and 0.2% sodium cholate. After the addition of solvent (TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hours. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally ultrafiltration and diafiltration. Hyper RHO S/D Mini-Dose is then incubated in the final container for 21-28 days at 20-27°C. Hyper RHO S/D Mini-Dose is formulated as a 15-18% protein solution at a pH of 6.4-7.2 in 0.21-0.32 M glycine. One dose of Hyper RHO S/D Mini-Dose contains not less than one-sixth the quantity of Rh o (D) antibody contained in one standard dose of Rh o (D) Immune Globulin (Human), and it will suppress the immunizing potential of 2.5 mL of Rh o (D) positive packed red blood cells or the equivalent of whole blood (5 mL). The quantity of Rh o (D) antibody in Hyper RHO S/D Mini-Dose is not less than 250 IU.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for Hyper RHO S/D Mini-Dose has been validated in laboratory studies. Human Immunodeficiency Virus, Type 1 (HIV-1), was chosen as the relevant virus for blood products; Bovine Viral Diarrhea Virus (BVDV) was chosen to model Hepatitis C virus; Pseudorabies virus (PRV) was chosen to model Hepatitis B virus and the Herpes viruses; and Reo virus type 3 (Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at two steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: the precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.
Rh sensitization may occur in nonsensitized Rh o (D) negative women following transplacental hemorrhage resulting from spontaneous or induced abortions. 1-2 The risk of sensitization is higher in women undergoing induced abortions than in those aborting spontaneously. 1-3
Hyper RHO S/D Mini-Dose is used to prevent the formation of anti-Rh o (D) antibody in Rh o (D) negative women who are exposed to the Rh o (D) antigen at the time of spontaneous or induced abortion (up to 12 weeks' gestation). 3-5 Hyper RHO S/D Mini-Dose suppresses the stimulation of active immunity by Rh o (D) positive fetal erythrocytes that may enter the maternal circulation at the time of termination of the pregnancy.
The amount of anti-Rh o (D) in Hyper RHO S/D Mini-Dose has been shown to effectively prevent maternal isosensitization to the Rh o (D) antigens following spontaneous or induced abortion occurring up to the 12th week of gestation. 6-8 After the 12th week of gestation, a standard dose of Hyper RHO S/D Full Dose is indicated.
In a clinical study in eight healthy human adults receiving another hyperimmune immune globulin product treated with solvent/detergent, Rabies Immune Globulin (Human), Hyper RAB ™ S/D, prepared by the same manufacturing process, detectable passive antibody titers were observed in the serum of all subjects by 24 hours post injection and persisted through the 21 day study period. These results suggest that passive immunization with immune globulin products is not affected by the solvent/detergent treatment.
Hyper RHO S/D Mini-Dose is recommended to prevent the isoimmunization of Rh o (D) negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation provided the following criteria are met:
Note: Rh o (D) Immune Globulin (Human) prophylaxis is not indicated if the fetus or father can be determined to be Rh negative. If the Rh status of the fetus is unknown, the fetus must be assumed to be Rh o (D) positive, and Hyper RHO S/D Mini-Dose should be administered to the mother.
FOR ABORTIONS OR MISCARRIAGES OCCURRING AFTER 12 WEEKS' GESTATION, A STANDARD DOSE OF Rh o (D) IMMUNE GLOBULIN (HUMAN) IS INDICATED.
Hyper RHO S/D Mini-Dose should be administered within 3 hours or as soon as possible after spontaneous passage or surgical removal of the products of conception. However, if Hyper RHO S/D Mini-Dose is not given within this time period, consideration should still be given to its administration since clinical studies in male volunteers have demonstrated the effectiveness of Rh o (D) Immune Globulin (Human) in preventing isoimmunization as long as 72 hours after infusion of Rh o (D) positive red cells. 9
None known.
HyperRHO S/D Mini-Dose is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly hepatitis C. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Talecris Biotherapeutics, Inc. [1-800-520-2807].
The physician should discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient.
NEVER ADMINISTER HYPER RHO S/D MINI-DOSE INTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. ADMINISTER ONLY TO WOMEN POSTABORTION OR POSTMISCARRIAGE OF UP TO 12 WEEKS' GESTATION. NEVER ADMINISTER TO THE NEONATE.
Hyper RHO S/D Mini-Dose should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations.
The attending physician who wishes to administer Hyper RHO S/D Mini-Dose to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.
As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.
Although systemic reactions to immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic symptoms.
Other antibodies in the Hyper RHO S/D Mini-Dose preparation may interfere with the response to live vaccines such as measles, mumps, polio or rubella. Therefore, immunization with live vaccines should not be given within 3 months after Hyper RHO S/D Mini-Dose administration.
Animal reproduction studies have not been conducted with Hyper RHO S/D Mini-Dose. It is also not known whether Hyper RHO S/D Mini-Dose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
It should be again noted, however, that Hyper RHO S/D Mini-Dose is not indicated for use during pregnancy and it should be administered only postabortion or postmiscarriage.
Safety and effectiveness in the pediatric population have not been established.
Reactions to Hyper RHO S/D Mini-Dose are infrequent in Rh o (D) negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human globulin is extremely rare, it has occurred.
NEVER ADMINISTER HYPER RHO S/D MINI-DOSE INTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. ADMINISTER ONLY TO WOMEN POSTABORTION OR POSTMISCARRIAGE OF UP TO 12 WEEKS' GESTATION. NEVER ADMINISTER TO THE NEONATE.
One syringe of Hyper RHO S/D Mini-Dose provides sufficient antibody to prevent Rh sensitization to 2.5 mL Rh o (D) positive packed red cells or the equivalent (5 mL) of whole blood. This dose is sufficient to provide protection against maternal Rh sensitization for women undergoing spontaneous or induced abortion of up to 12 weeks' gestation.
Hyper RHO S/D Mini-Dose should be administered within 3 hours or as soon as possible following spontaneous or induced abortion. If prompt administration is not possible, Hyper RHO S/D Mini-Dose should be given within 72 hours following termination of the pregnancy.
Hyper RHO S/D Mini-Dose is administered intramuscularly, preferably in the anterolateral aspects of the upper thigh and the deltoid muscle of the upper arm. The gluteal region should not be used routinely as an injection site because of the risk of injury to the sciatic nerve. If the gluteal region is used, the central region must be avoided; only the upper, outer quadrant should be used. 10
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Rh o (D) Immune Globulin (Human) -- Hyper RHO ™ S/D Mini-Dose is supplied with a syringe and an attached UltraSafe® Needle Guard for your protection and convenience. Please follow instructions below for proper use of syringe and UltraSafe® Needle Guard.
|
|
A number of factors beyond our control could reduce the efficacy of this product or even result in an ill effect following its use. These include improper storage and handling of the product after it leaves our hands, diagnosis, dosage, method of administration, and biological differences in individual patients. Because of these factors, it is important that this product be stored properly and that the directions be followed carefully during use.
Hyper RHO S/D Mini-Dose package contains 10 single dose syringes.
| NDC Number | Size |
| 13533-631-06 | Syringe (10 pack) |
Store at 2-8°C (36-46°F). Do not freeze.
CAUTION
Rx only
U.S. federal law prohibits dispensing without prescription.
USA 08907652
(Published January 2005)
Talecris Biotherapeutics, Inc.
Research Triangle Park, NC 27709
U.S. License No. 1716
 |
Information About
Pregnancy Protection
The Rh factor is one of many blood group antigens found on the surface of red blood cells. If you have this antigen you are considered Rh positive. If you don't, then you are considered Rh negative. Everyone is either Rh positive or Rh negative. One type is neither better nor worse than the other, only different.
Your Rh factor is important if you are an Rh negative woman and you become pregnant, or if you receive a blood transfusion.
If you have Rh negative blood, there are two situations that can affect you:
When an Rh negative woman has Rh positive antibodies in her blood and the baby she is carrying is Rh positive, the antibodies could possibly enter the baby's bloodstream, attack the baby's red blood cells and cause hemolytic disease of the newborn. At birth, the infant suffering from hemolytic disease may be jaundiced and anemic or suffer permanent damage of the brain and central nervous system which may result in mental retardation, hearing loss, or cerebral palsy. Extensive medical care can be required, including an exchange transfusion, in which all of the baby's blood is replaced. This usually stops the destruction of the baby's red blood cells and gives the infant a chance to survive.
The risk of hemolytic disease of the newborn is slight with the first baby, but increases with each successive pregnancy.
Hyper RHO ™ S/D, Rh o (D) Immune Globulin (Human) can prevent hemolytic disease of the newborn, provided Rh positive antibodies do not already reside in your bloodstream.
Hyper RHO S/D is a specially prepared gamma globulin with a high level of preformed antibodies against Rh positive blood cells. The injection of Hyper RHO S/D destroys any Rh positive blood cells that may have entered the mother's bloodstream and prevents the mother's immune system from producing Rh positive antibodies; thus protecting the baby from developing hemolytic disease.
Hyper RHO S/D Full Dose is administered during pregnancy if you fall into a high-risk category. For example, you are at risk of producing Rh positive antibodies if you have an amniocentesis procedure performed, or if you have a miscarriage or other termination of pregnancy at or beyond 13 weeks' gestation.
Laboratory findings have shown that some Rh negative women develop Rh positive antibodies during the last weeks of pregnancy even without an antibody-stimulating event. As a preventive measure, your physician will probably recommend the first injection of Hyper RHO S/D Full Dose at the 28th week of pregnancy.
In both of the above situations, if the blood type of the father or baby can be determined to be Rh negative, an injection of Hyper RHO S/D is not required.
Another injection of Hyper RHO S/D Full Dose is administered within 72 hours of delivery of an Rh positive baby.
Hyper RHO S/D Full Dose may be used to prevent isoimmunization in Rh negative individuals who have been transfused with Rh positive red blood cells or blood components containing red blood cells.
A single dose of Hyper RHO S/D Mini-Dose may be prescribed for an Rh negative woman instead of Hyper RHO S/D Full Dose in the event of miscarriage or other termination of pregnancy occurring prior to 13 weeks' gestation. Hyper RHO S/D Mini-Dose is not required if the blood type of the father or fetus can be determined to be Rh negative.
Hyper RHO S/D provides protection only if you have not already produced Rh positive antibodies. Women who have developed antibodies through previous pregnancy, miscarriage, other termination of pregnancy, or blood transfusion cannot be protected by Hyper RHO S/D. This is why with each pregnancy it is important to have Hyper RHO S/D injections within the prescribed time period.
You may feel a temporary soreness at the site of the injection. You may also have a slight and temporary change in body temperature. In very rare instances, an allergic type of reaction can occur, for which your physician will take appropriate measures.
Your physician can answer any questions you may have about receiving a Hyper RHO S/D injection to prevent hemolytic disease of the newborn. If you know that you are Rh negative and you are pregnant, you should discuss your situation with your physician. Today, with Hyper RHO S/D, hemolytic disease of the newborn can be reduced to its lowest possible rate of incidence.
08907652 (Published January 2005)
Talecris Biotherapeutics, Inc.
Research Triangle Park, NC 27709 USA
U.S. License No. 1716
1
Rh positive (+) father.
 |
2
Pregnancy: Rh- mother is carrying Rh+ baby.
 |
3
The passage of Rh+ blood from the baby to the mother's bloodstream happens most often at delivery, but can also occur during miscarriage, other termination of pregnancy, amniocentesis, or due to injury or trauma.
 |
4
Rh+ antibodies stay in your bloodstream, ready to attack invading Rh+ blood cells, for many years to come.
 |
5
Next pregnancy, mother's Rh+ antibodies enter baby's Rh+ bloodstream, attacking baby's blood cells and causing hemolytic disease of the newborn.
 |
1
You will probably be given two injections of Hyper RHO S/D Full Dose, one at the 28th week of your pregnancy and another within 72 hours of delivery, miscarriage or other termination of pregnancy. A single injection of Hyper RHO S/D Mini-Dose may be prescribed instead of Hyper RHO S/D Full Dose in the event of miscarriage or other termination of pregnancy occurring prior to 13 weeks' gestation.
 |
2
Hyper RHO S/D immunization prevents formation of mother's own Rh+ antibodies. Mother's bloodstream remains free of Rh+ antibodies.
 |
3
Next pregnancy, baby develops normally. Hyper RHO S/D should be administered following delivery, miscarriage, or other termination of pregnancy to continue protection if baby is Rh+.
 |